Luciano Spalletti said that Juventus players need to look at themselves after Gleison Bremer criticised his teammates for not showing enough character in Sunday's 3-0 Serie A defeat against Lazio, but says that he will be doing the same of himself: 'I need to ask myself questions and find the answers'.
The tension is palpable in Juventus circles following Sunday's 3-0 defeat at home against Lazio, which has left the Bianconeri eight points off the league leaders after just seven matches. They are currently worse off in terms of points than they were at the same stage of the 2025-26 season, just before Igor Tudor was dismissed from his position as head coach.
TURIN, ITALY – OCTOBER 18: Oliver Provstgaard Nielsen of SS Lazio scores the opening goal during the Serie A match between Juventus and SS Lazio at Allianz Stadium on October 18, 2026 in Turin, Italy. (Photo by Valerio Pennicino/Getty Images)
It was a miserable evening for Juventus supporters, some of whom turned on each other and began fighting in the stands. They were heavily criticised in Monday morning's newspapers and defender Bremer also chastised his teammates, claiming 'I can't carry everyone'.
"It is true, the coach gives indications, but we are the ones who need to put it into action on the field," said the Juventus defender after full-time on Sunday.

#juventus #turin #october

Ken Urker's final hours are drawing massive attention following his sudden death at 33. The former fiancé of Gypsy Rose Blanchard left behind more than a grieving family, as new details have emerged about what he was doing shortly before he died.
From one of his final social media appearances to the growing tension surrounding his passing, several pieces of Ken's final days have now come into focus.
Yet, amid the public attention surrounding his life and death, there was also a quieter side of him that remained largely hidden from the public.
Instagram | Gypsy Rose Blanchard
Ken went live on TikTok on Wednesday night, according to TMZ. The footage offered very little indication of what was happening, although he appeared to be traveling somewhere while strong wind could be heard throughout the recording.

#rose #blanchard #TikTok

WASHINGTON (AP) — The U.S. military is dispatching roughly 9,000 troops aboard a group of ships to the Middle East, a U.S. official said Thursday. The bolstering of the American military presence comes as President Donald Trump warned anew that new strikes against Iran could be on the horizon.
The troop movement, which includes a third aircraft carrier, underscores the rapidly evolving dynamic of Trump's war against Iran as he ponders his next move, with midterm elections in the United States looming large and new signs that the nature of the conflict may be becoming more complex.
Trump has threatened that a post-midterm election escalation — despite his initial promises to Americans of a campaign that would last a matter of weeks — remains a viable option. Further complicating matters, Trump told reporters Thursday that early indications suggest that Iran is linked to the FlyDubai co-pilot who stabbed his captain and tried to crash an Israel-bound flight on Wednesday.
In an exchange with reporters at the White House, Trump raised the connection when asked by a reporter if there were any links between the pilot behind the attack and Tehran.
"I would say the answer, based on what I'm hearing, is 'yes,' but we're working on it right now," Trump said, without offering details.

#military #reporters #washington #middle

Bloom Energy Corporation (NYSE:BE) garnered significant investor attention after it unveiled a new 800V DC-native fuel-cell power architecture on September 16, designed to supply continuous direct current to the next generation of AI data centers.
These solid-oxide fuel cells can generate continuous 800V DC power natively, rather than producing AC power that then has to be converted into DC that AI computing equipment ultimately consumes. This potentially removes several conversion stages, such as transformers and switchgear, thus lowering capital cost and energy losses.
Bloom claims that its technology can cut non-compute capital expenditures for a 1 GW data center by $3.6 billion, or 27%, and lower five-year total cost of ownership by $5.5 billion, or 9%, compared to traditional AC-based infrastructure.
With this technology, Bloom Energy is targeting one of the biggest bottlenecks in the ongoing AI boom – securing large amounts of reliable power quickly and economically. If 800V DC becomes widely adopted across AI data centers, the company will benefit not only from the soaring power demand, but also from a broader shift in how that power is generated and delivered.
Bloom Energy pointed to Nvidia's planned adoption of 800V DC architecture beginning with Rubin Ultra and Kyber systems as an indication of where data center power infrastructure is heading. In its 2026 Mid-Year Data Center Power Report, Bloom claimed that data center leaders expect DC-based architectures to account for 58% of new deployments by 2030, potentially creating a significant market for technologies designed around direct-current power delivery.

#energy #architecture

In the end, Kevin Warsh's Federal Reserve acquitted itself well. For all the uncertainty he had sparked at the previous meeting of the Federal Open Market Committee, when he refused to provide any indication of what he was prepared to do to tame stubborn inflation, the chair on Wednesday presided over a unanimous decision to raise interest rates for the first time in three years.
"Today's action starts to show that we're serious about this," he said at the press conference after the meeting, with "this" meaning inflation in excess of the Fed's 2% target for over five years. Welcome though it was, his embrace of economic orthodoxy nonetheless did little to dispel the Keystone Cops quality of governance in Donald Trump's US.
Warsh's resolve – raising rates just a few weeks before elections that will determine whether Republicans retain control of Congress – appeared even more resolute in the face of a veiled threat from White House economic adviser Kevin Hassett, who pointed out to his chums on Fox that "if you want an independent Fed, then one thing the Fed does is it stays out of the way of elections".
The central bankers' parsimonious comments in the press conference following the meeting made a sharp contrast with the more unhinged commentary from other members of the administration, including the president himself, who earlier this month celebrated the resilience of the labor market with a mind-boggling threat to "STOP TRADING WITH COUNTRIES WITH WHICH WE HAVE A DEFICIT" unless the Fed cut interest rates.
Trump has yet to turn on Warsh in the way he did on his predecessor, Jerome "numbskull" Powell. But the signs are ominous. After the rate hike, Trump went ballistic – spewing more of the random, incoherent thoughts that have become his trademark. "Interest Rates in the United States should be 1%, or less, because we are the Best Credit in the World," he wrote on social media, despite recalcitrant inflation and a budget deficit that is likely to exceed $2tn this year. He again demanded the powers that be to "LOWER THE INTEREST RATES FOR THE UNITED STATES OF AMERICA, AND FAST!"

#rates #federal #states

Interested in Axsome Therapeutics, Inc.? Here are five stocks we like better.
Auvelity remains Axsome's main growth driver: It generated more than $180 million of the company's $218.4 million in second-quarter revenue, while its new Alzheimer's disease agitation indication is supported by an expanded sales force of more than 600 representatives.
The commercial portfolio is expanding: Sunosi continues to grow, and SYMBRAVO revenue increased 30% sequentially in the second quarter as Axsome expanded its migraine sales team.
Pipeline and finances are strengthening: Axsome has several late-stage programs and upcoming clinical milestones, ended the quarter with $320 million in cash, and said it is approaching cash-flow positivity.
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

#second

With just over three months left in the year, the S&P 500 (SNPINDEX: ^GSPC) is up 11% year to date. If it manages to stay there, it will end 2026 with four consecutive years of double-digit gains, a feat not accomplished since 1999 -- incidentally, right before it crashed and lost nearly 50% of its value. It lost that over three years, and it didn't reach a new high until mid-2007. Many companies went out of business then as the dot-com bubble burst.
If history is any indication of what's about to happen, every investor should be doing this one thing right now.
Missed AI's "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ***** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
The artificial intelligence (AI) revolution is real, but the hype might not exactly align with reality. Some well-established AI powerhouses, like Nvidia and Alphabet, don't look expensive at today's prices. They trade at 14 and 23 times forward, one-year earnings, respectively. However, other, smaller stocks look riskier as their valuations soar.
Bloom Energy, for example, trades at 53 times forward, one-year earnings, and only recently became profitable, while Marvell Technology trades at 33 times earnings. CoreWeave isn't yet profitable. It appears that investors are willing to take a chance on these stocks for the massive expected payoff as they grow.

#years #right #lost

On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO).
The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 diabetes. Neither party will have continuing financial obligations to the other. Once termination becomes effective and the rights revert, management plans to initiate multiple programs across rare and large indications.
The investment question is whether greater control over future products can justify the resources needed to develop them.
Ascendis Pharma A/S (NASDAQ:ASND) would regain flexibility over which indications to pursue, how quickly to advance candidates, and whether to seek another partner. Successful independent development could retain more of a product's commercial economics, while a new collaboration could provide another way to share costs and risk.
Monthly dosing offers a clear development objective. If clinical studies demonstrate effective treatment with acceptable tolerability, fewer injections could make long-term therapy more convenient. That potential benefit would matter most if it helps patients stay on treatment without sacrificing outcomes.

#ascendis #pharma #asnd #regain

NEW YORK (AP) — President Donald Trump said Friday that he was barring CNN, MS NOW and Politico from the White House due to what he called unfavorable coverage and "fake news," and threatened that more such media bans could be coming — the latest salvo in the president's increasingly aggressive response to media coverage he finds unfavorable.
Like many of Trump's other confrontations with news organizations — some of which are playing out in the legal arena — this threat has potential First Amendment implications. There was no immediate indication, though, that he was following through.
Trump wrote on his social media site that effective immediately, "I am banning" CNN, MS NOW and Politico "from the White House as a result of their constant 'reporting' FAKE NEWS!" Minutes later, speaking at an event in the Oval Office, Trump was asked to explain his statement.
"Because they're fake news," he said. "You get so tired of reading and seeing fake news. When you look at CNN, it's just fake. That's why their ratings are no good. When you look at MS NOW … , it's fake news."
"And when you look at Politico ... the stories they wrote are fake. So there's a lot of news and there may be others to join them, and maybe they can get better," he said. "But our country has to have honest news."

#fake #look #House

Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-severe atopic dermatitis. The primary measure was the percentage change from baseline in Eczema Area and Severity Index, or EASI, at week 12. No tested dose met the primary or secondary endpoints, and development in that indication will stop.
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p

Is there anything prettier than a consistently uptrending stock price chart? I'm drawn to these types of charts. I've always thought a consistent uptrend is an indication of strong buying power for a stock. However, while I can tell you if a chart looks like a consistent, methodical trend, it's hard to define it using data, which is necessary to create an indicator. That's why, until now, I've never put numbers behind my theory.
I won't go into the details, but using moving averages over various time frames, I've created a ranking system for stocks with the most consistent uptrends and downtrends over the past three months. Using this ranking system, Docusign (DOCU) is one of the top uptrending stocks. That's a pretty chart, if I do say so myself. When I see a chart like this, I think, why would it stop now?
In this week's article, I'll test my theory with actual numbers and see if DOCU and other stocks like it are good bets, like my instincts have always led me to believe.
For this study, I went back to 2024 and picked the 18th of each month, which corresponds to the end of this week. I used my trend ranking system to find the 30 stocks in the strongest uptrends and the 30 in the most consistent downtrends. Then, I tracked how each group performed over the next month of trading. The table below summarizes the results.
My instincts look correct based on the average returns of the stocks. The top uptrending stocks averaged a return of 2.15% over the next month, while the most consistently downtrending stocks averaged a return of 1.57%. The other stocks averaged 1.84%, falling between the two groups.

#like #using

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#stage #survival

Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly's rapid share capture an important sign that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use.
The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.
The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and **** an, potentially expanding the addressable market beyond weight management.
The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.

#patients #weight #c

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#biontech #survival

Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly's rapid share capture an important sign that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use.
The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.
The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and ***** an, potentially expanding the addressable market beyond weight management.
The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.

#weight

TOKYO (AP) — **** an's air force said one of its long-distance surveillance drones is believed to have crashed into the sea during a flight Tuesday off the country's northwestern coast.
There were no immediate details on the nature of the mission of the uncrewed RQ-4B aircraft, also known as Global Hawk. So far, there was no indication of foul play, but officials said the cause of the presumed crash was under investigation.
The Air Self-Defense Force said the drone had trouble connecting with a communication device about one and a half hours after taking off from the Misawa Air Base. Three minutes later, it disappeared from the radar and was last seen 50 kilometers (31 miles) off the coast of Tottori, the ASDF said.
Later Tuesday, a fighter jet and a **** an Coast Guard patrol ship spotted debris believed to be from the Global Hawk. After examining photos of the debris, the ASDF said the drone is believed to have crashed just after disappearing from the radar.
The cause of the Global Hawk's presumed crash is still under investigation, the ASDF said. There have been no reports of injury or damage related to the crash.

#asdf #coast #crash

Is there anything prettier than a consistently uptrending stock price chart? I'm drawn to these types of charts. I've always thought a consistent uptrend is an indication of strong buying power for a stock. However, while I can tell you if a chart looks like a consistent, methodical trend, it's hard to define it using data, which is necessary to create an indicator. That's why, until now, I've never put numbers behind my theory.
I won't go into the details, but using moving averages over various time frames, I've created a ranking system for stocks with the most consistent uptrends and downtrends over the past three months. Using this ranking system, Docusign (DOCU) is one of the top uptrending stocks. That's a pretty chart, if I do say so myself. When I see a chart like this, I think, why would it stop now?
In this week's article, I'll test my theory with actual numbers and see if DOCU and other stocks like it are good bets, like my instincts have always led me to believe.
For this study, I went back to 2024 and picked the 18th of each month, which corresponds to the end of this week. I used my trend ranking system to find the 30 stocks in the strongest uptrends and the 30 in the most consistent downtrends. Then, I tracked how each group performed over the next month of trading. The table below summarizes the results.
My instincts look correct based on the average returns of the stocks. The top uptrending stocks averaged a return of 2.15% over the next month, while the most consistently downtrending stocks averaged a return of 1.57%. The other stocks averaged 1.84%, falling between the two groups.

#chart #like #ranking #month

Sarah Pidgeon, who is nominated for Outstanding Lead Actress in a Limited or Anthology Series or Movie for Love Story: John F. Kennedy Jr. & Carolyn Bessette at the Emmys this evening, attended the BAFTA TV Tea Party held at The Maybourne Beverly Hills on Sunday.
Christopher Polk/Deadline via Getty Images
If you were worried that Sarah's awards season run was going to be a succession of black dresses, fear not, because she switched gears in a Givenchy Pre-Fall 2026 oxblood leather dress.
There is considerably more going on here than we've seen from Sarah on the red carpet recently. The folded, asymmetric neckline gives the leather some shape and interest, while the oxblood colour is a welcome change of pace.
For me, this is the kind of look that makes Sarah's style more interesting. The black dresses have served her well and become something of a signature, but I'm hoping this is an indication of what she could give us as awards season gathers pace.

#sarah #season #leather

It has been a rollercoaster year for the "Magnificent Seven" stocks, the name given to tech ******* ans Nvidia, Apple, Microsoft, Amazon, Alphabet, Tesla, and Meta Platforms (NASDAQ: META). Of the group, only Meta and Tesla are in the red for the year, down 1.2% and 18.8%, respectively, through market close on Sept. 10.
Both have their fair share of issues, but Meta is a struggling stock that seems to have plenty of upside from its current level. And if history is any indication of what's possible, you may regret not investing while it's having an off year.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
No single issue is dragging down Meta's stock; it's a combination of factors, with the two main ones being its AI spending and its ongoing regulatory issues.
This year, Meta is slated to spend between $130 billion and $145 billion on AI-related projects, such as building data centers and other infrastructure. In the second quarter (Q2), it spent $31 billion, which, for perspective, is more than all but 26 public companies have made in profits in their past four quarters combined.

#tesla #Stock

The dream for most football players is to play in the NFL eventually, and wide receiver Antonio Williams will officially realize that dream this coming Sunday when the Washington Commanders take on the Philadelphia Eagles.
Williams was a third-round draft pick out of Clemson. His 2024 campaign is probably the best indication of what he is capable of, after having over 900 receiving yards and leading the ACC in touchdowns that season with 11. Washington hopes to bring that kind of production to the Commanders this season, though he'll first have to get over his first-game jitters.
"I feel like if you ain't a little nervous, you don't care. And that's how I approach the game. So, yeah, when it comes out, that first play, I'll probably have a little jitters. But then once the snap goes, then it's game time."
Williams is not a stranger to a capacity stadium and electric game atmosphere. Clemson's Death Valley is well-known in college for its game atmosphere and traditions that make it a difficult place to play, and the Tigers traveled to some hostile places during Williams' time in college. However, it is different when you are playing in the NFL.
Also, Williams and the rest of the Commanders rookie class will not be able to experience a Washington Commanders home game until Week 3 against the Seattle Seahawks. This is the first time since 2012 that Washington has started their season with back-to-back road games.

#williams #play #season #dream

Bayern Munich and SSV Ulm 1846 are continuing their partnership focused on developing the next generation of footballers.
The two clubs have extended their cooperation agreement for another year, meaning the partnership will now run through June 2027 per iMiaSanMia. Bayern Munich and Ulm have been working together in youth development since the beginning of 2021, with both clubs aiming to create better opportunities and pathways for young players.
The extension is another indication of Bayern Munich's continued focus on building relationships with clubs that can contribute to the development of young talent.
For SSV Ulm 1846, working alongside one of Germany's biggest clubs provides an opportunity to benefit from Bayern Munich's experience and expertise in youth football. For Bayern Munich, partnerships such as this can help strengthen its scouting and development network while identifying players with the potential to progress further.
The relationship has now lasted more than five years, and both clubs clearly see value in continuing it.

#munich #continuing #partnership #Youth

On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints at week 24 in patients with eosinophilic esophagitis. These benefits were sustained through week 52 across both tested doses, accompanied by a safety profile consistent with its approved indications. While CROSSING highlights their joint R&D success, a closer look at their standalone financial performance reveals distinct growth trajectories.
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.

#revenue #astrazeneca #increased #products

Last season, Arizona soccer (2-3-1) ended the season ranked No. 239 in Division I in goal differential at -6. With Big 12 play still to come, the Wildcats are No. 188 with a -1 goal differential. That's lower than their first opponent this week.
Northern Arizona (2-3-1) comes into Thursday's match ranked No. 159 with a +1 differential.
NAU is a team Arizona head coach Becca Moros and her Wildcats see a lot. Not only do the two teams play each other during the regular season most years, but they also face off during spring games.
If the last regular season game between the two is any indication, Arizona should have the opportunity to get itself right against the Lumberjacks. The Wildcats edged past NAU by the score of 1-0 in an exhibition in Flagstaff last season, but they had much more success when the two teams met in Tucson during the regular season two years ago. That match was a 5-0 Arizona victory. The last time the Wildcats scored five goals was almost exactly a year ago when they defeated GCU 5-2 on Sept. 14.
Last week's match against Dartmouth proved that it may not be so easy, though. Moros and her players felt they did enough to win that match, but they didn't capitalize on their chances. They outshot the Big Green 14-1 and had a 5-1 edge in shots on goal, but Dartmouth's only shot went into the net.

#wildcats

Barcelona have received a timely boost with Gavi back in contention for upcoming matches against Feyenoord and Levante after recovering from the knee problem that briefly interrupted his start to the season.
According to Mundo Deportivo, the 22-year-old midfielder is now expected to feature in Hansi Flick's rotation plans, beginning with Wednesday's meeting with Feyenoord.
Gavi returned to the squad at the weekend after missing Barcelona's home victories over Athletic Club and Rayo Vallecano because of discomfort.
He was named among the substitutes for Sunday's 5-0 win at Valencia but did not enter the game. His presence on the bench was nevertheless another indication that the injury is behind him.
Gavi's injury initially raised concerns after Barcelona's opening-day victory at Elche.

#gavi #injury #levante

Robert De Niro's political reputation took an unexpected turn according to an AI image Donald Trump shared on Truth Social. The post depicted the veteran actor wearing a pro-Trump message, despite De Niro's long record of publicly opposing the president and his administration.
Donald Trump posted the apparently AI-created picture on Truth Social Sunday, showing Robert De Niro holding a red shirt emblazoned with "TRUMP IS MY PRESIDENT." The president added his own jab, writing, "Even this jerk is beginning to get it," while offering no indication that the actor had actually changed his political position (via The Independent).
De Niro has spent decades building one of Hollywood's most respected acting careers. His résumé includes Taxi Driver, Raging Bull and Goodfellas, while his performances have earned him two Academy Awards. Away from the screen, however, he has become equally recognizable for his outspoken opposition to Trump.
That stance stretches back years. Before the 2016 election, De Niro branded Trump a "pig," "punk," and "bulls*** artist." In 2019, he escalated his criticism by calling Trump "evil" and saying he could not wait to see him imprisoned. His latest comments to USA Today last month remained just as blunt.
"I don't even use the word 'hope' anymore," De Niro said of Trump's administration, warning that it could damage America and other parts of the world. "He's just going to destroy not only the country, but other parts of the world. It's insane. That's a big concern of mine, and I think a lot of people now," the actor continued.

#truth

Mikel Arteta hailed a "beautiful" win after **** nal came from behind to beat Chelsea 2-1 at the Emirates Stadium.
The Premier League champions required a response after conceding for the first time this season, Morgan Rogers stunning home fans into silence with a volleyed goal after 77 seconds before the hosts hit back against a Chelsea side still finding its feet under Xabi Alonso.
Kai Havertz netted for the third time against his old club to equalise midway through the first half – a near-post effort that perhaps ought to have been kept out by Emiliano Martinez – then produced a sumptuous dummy to clear Martin Odegaard's path to goal, with the captain lashing home the winner in the 50th minute.
"I think it was an exceptional performance," said Arteta. "I enjoyed every minute of it, from the beginning to the end. The beginning was tough but I enjoyed it because the team reacted in a spectacular way. The determination, the quality. It was beautiful. It was a fascinating game for the spectator.
"I think it's an indication for us of how capable we are to perform at an even higher level than last season. We still have a lot to grow and a lot to offer."

#season #minute

The Diamondbacks came into the game looking for a series win, and with a little bit of luck, putting some more ***** e between their competition for the final NL Wild Card spot. Having Eduardo Rodriguez on the mound was a point in their favor, but the offense still RVSP'd maybe when invited to the game.
The Diamondbacks were quiet in the top of the first, with the only baserunner being a Geraldo Perdomo hit by pitch, and that allowed the Astros to strike first. E-Rod got Jeremy Pena to ground out, but Yordan Alvarez absolutely clobbered one for a solo home run. That was the first indication that Rodriguez didn't have his best stuff today, but the next few batters hammered that home, even if there wasn't much damage done. He walked both Isaac Paredes and Christian Walker, but alternated those walks with a line out from Jose Altuve and got out of the jam with a Nelson Velasquez strike out. 0-1 Astros
This, of course, did raise some concerns amongst the faithful about the early need to score more than one run. That's been a challenge for the Diamondbacks, last night's four run outbreak aside. The offense decided to do some to ***** uage those fears, but did not manage to score multiple runs right away. Corbin Carroll started off the second inning with a double, advanced on a sac bunt from Tommy Troy, and then scored on a sac fly from James McCann. Illdemaro Vargas tried to keep things going with a two out single, but Lawler was unable to step up and ended the inning with a line out to third. Tied 1-1
Rodriguez issues with command continued right away in the bottom of the second, walking Dalton Varsho. Never a good idea to walk someone like him, as he showed when he stole second to get into scoring position two outs later. Too late for it to matter, though, as Jeremy Pena only saw three pitches and flew out to end the inning.
The third inning was… something. Perdomo singled to lead off the inning, bringing Ketel Marte to the plate. Marte got an 86 MPH changeup down and away and turned it around for what looked like an easy single. The only with that is the ball also acted as a heat seeking missel straight to Perdomo's helmet. He hit the ground immediately and quickly found himself surrounded by trainers from both teams. Eventually he left under his own power to a nice ovation from the Houston crowd, as one does.

#astros

By Dmitry Antonov and Gleb Bryanski
MOSCOW, Sept 5 (Reuters) - Russian President Vladimir Putin held more than three hours of "highly useful" talks on Saturday with two U.S. envoys seeking a deal to end the Ukraine war, a Kremlin aide said, but he gave no indication of any breakthrough.
The ‌aide, Yuri Ushakov, said Americans Steve Witkoff and Jared Kushner "outlined a number of ideas regarding possible avenues for a settlement". Ushakov did not say what ‌these ideas were.
He said Putin had told the pair that Russia was making "real progress" on the battlefield and was confident of achieving its goals, while stressing the necessity of addressing "all the root causes of the conflict".
These are statements that Moscow has made repeatedly since Putin launched the full-scale invasion of Russia's smaller neighbour in February 2022. Both sides have intensified long-range air strikes in recent weeks while the front lines remain largely static.

#putin #aide #antonov #gleb

The NFL had an offseason in which there was a record-tying 10 head coaching changes.
Next offseason might not see that many changes, but there will be some. NFL teams have become increasingly impatient and quick to change head coaches. There's even a notion that Green Bay Packers coach Matt LaFleur, who has won 65.4% of his games and has just one losing season out of seven, could be on the hot seat if the Packers don't do well enough this season. Whether that comes to pass, it shows how tough of a profession it can be.
Here are the coaches on the hottest seats heading into the season:
Glenn was a candidate to be one and done after a very disheartening 3-14 season. Glenn stayed, but he replaced 12 of the 22 **** istants from last year's staff. That type of turnover is a clear indication that the head coach needs to show improvement the following season. If the Jets are as uncompetitive as they were in Glenn's first season, it seems likely that a change would be made. And the Jets have plenty of roster holes heading into the season.
Jets head coach Aaron Glenn went 3-14 in his first season leading the team. (Photo by Evan Bernstein/Getty Images)

#Jets #coach #packers #offseason